ATC Group: J01MA23 Delafloxacin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J01MA23 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J01 Antibacterials for systemic use
3 J01M Quinolone antibacterials
4 J01MA Fluoroquinolones
5 J01MA23

Active ingredients in J01MA23

Active Ingredient Description
Delafloxacin

Delafloxacin inhibits bacterial topoisomerase IV and DNA gyrase (topoisomerase II), enzymes required for bacterial DNA replication, transcription, repair, and recombination.

Related product monographs

Title Information Source Document Type  
QUOFENIX Powder for concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
QUOFENIX Tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Croatia (HR)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Italy (IT)

Lithuania (LT)

Poland (PL)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.